{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:21:47Z","timestamp":1790198507275,"version":"4.1.0"},"reference-count":43,"publisher":"American Diabetes Association","issue":"10","license":[{"start":{"date-parts":[[2016,9,22]],"date-time":"2016-09-22T00:00:00Z","timestamp":1474502400000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Cannabidiol (CBD) and \u03949-tetrahydrocannabivarin (THCV) are nonpsychoactive phytocannabinoids affecting lipid and glucose metabolism in animal models. This study set out to examine the effects of these compounds in patients with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>In this randomized, double-blind, placebo-controlled study, 62 subjects with noninsulin-treated type 2 diabetes were randomized to five treatment arms: CBD (100 mg twice daily), THCV (5 mg twice daily), 1:1 ratio of CBD and THCV (5 mg\/5 mg, twice daily), 20:1 ratio of CBD and THCV (100 mg\/5 mg, twice daily), or matched placebo for 13 weeks. The primary end point was a change in HDL-cholesterol concentrations from baseline. Secondary\/tertiary end points included changes in glycemic control, lipid profile, insulin sensitivity, body weight, liver triglyceride content, adipose tissue distribution, appetite, markers of inflammation, markers of vascular function, gut hormones, circulating endocannabinoids, and adipokine concentrations. Safety and tolerability end points were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Compared with placebo, THCV significantly decreased fasting plasma glucose (estimated treatment difference [ETD] = \u22121.2 mmol\/L; P &amp;lt; 0.05) and improved pancreatic \u03b2-cell function (HOMA2 \u03b2-cell function [ETD = \u221244.51 points; P &amp;lt; 0.01]), adiponectin (ETD = \u22125.9 \u00d7 106 pg\/mL; P &amp;lt; 0.01), and apolipoprotein A (ETD = \u22126.02 \u03bcmol\/L; P &amp;lt; 0.05), although plasma HDL was unaffected. Compared with baseline (but not placebo), CBD decreased resistin (\u2212898 pg\/ml; P &amp;lt; 0.05) and increased glucose-dependent insulinotropic peptide (21.9 pg\/ml; P &amp;lt; 0.05). None of the combination treatments had a significant impact on end points. CBD and THCV were well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>THCV could represent a new therapeutic agent in glycemic control in subjects with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc16-0650","type":"journal-article","created":{"date-parts":[[2016,8,29]],"date-time":"2016-08-29T22:03:21Z","timestamp":1472508201000},"page":"1777-1786","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":232,"title":["Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study"],"prefix":"10.2337","volume":"39","author":[{"given":"Khalid A.","family":"Jadoon","sequence":"first","affiliation":[{"name":"Division of Medical Sciences & Graduate Entry Medicine, School of Medicine, University of Nottingham, Derby, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart H.","family":"Ratcliffe","sequence":"additional","affiliation":[{"name":"St. Pancras Clinical Research, London, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Barrett","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Centre for Analytical Bioscience, University of Nottingham, Nottingham, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Louise","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, Research Centre for Optimal Health, University of Westminster, London, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Stott","sequence":"additional","affiliation":[{"name":"GW Pharmaceuticals, Cambridge, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy D.","family":"Bell","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, Research Centre for Optimal Health, University of Westminster, London, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saoirse E.","family":"O\u2019Sullivan","sequence":"additional","affiliation":[{"name":"Division of Medical Sciences & Graduate Entry Medicine, School of Medicine, University of Nottingham, Derby, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garry D.","family":"Tan","sequence":"additional","affiliation":[{"name":"NIHR Oxford Biomedical Research Centre, Oxford Centre for Diabetes, Endocrinology & Metabolism, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2016,9,13]]},"reference":[{"key":"2022031123345914900_B1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11154-011-9167-3","article-title":"Peripheral effects of the endocannabinoid system in energy homeostasis: adipose tissue, liver and skeletal muscle","volume":"12","author":"Silvestri","year":"2011","journal-title":"Rev Endocr Metab Disord"},{"key":"2022031123345914900_B2","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ajpath.2011.11.003","article-title":"The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications","volume":"180","author":"Horv\u00e1th","year":"2012","journal-title":"Am J Pathol"},{"key":"2022031123345914900_B3","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1007\/s00125-008-1048-2","article-title":"The endocannabinoid system in obesity and type 2 diabetes","volume":"51","author":"Di Marzo","year":"2008","journal-title":"Diabetologia"},{"key":"2022031123345914900_B4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2710.2010.01164.x","article-title":"An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity","volume":"36","author":"Christopoulou","year":"2011","journal-title":"J Clin Pharm Ther"},{"key":"2022031123345914900_B5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00213-009-1506-7","article-title":"The future of endocannabinoid-oriented clinical research after CB1 antagonists","volume":"205","author":"Le Foll","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"2022031123345914900_B6","doi-asserted-by":"crossref","first-page":"H610","DOI":"10.1152\/ajpheart.00236.2007","article-title":"Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption","volume":"293","author":"Rajesh","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2022031123345914900_B7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2353\/ajpath.2006.050500","article-title":"Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes","volume":"168","author":"El-Remessy","year":"2006","journal-title":"Am J Pathol"},{"key":"2022031123345914900_B8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1744-8069-6-16","article-title":"Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain","volume":"6","author":"Toth","year":"2010","journal-title":"Mol Pain"},{"key":"2022031123345914900_B9","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.jacc.2010.07.033","article-title":"Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy","volume":"56","author":"Rajesh","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2022031123345914900_B10","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ejphar.2013.10.002","article-title":"Cannabinoids alter endothelial function in the Zucker rat model of type 2 diabetes","volume":"720","author":"Stanley","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"2022031123345914900_B11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1476-5381.2008.00046.x","article-title":"5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats","volume":"156","author":"Resstel","year":"2009","journal-title":"Br J Pharmacol"},{"key":"2022031123345914900_B12","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl Psychiatry"},{"key":"2022031123345914900_B13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.schres.2011.04.017","article-title":"Cannabis with high cannabidiol content is associated with fewer psychotic experiences","volume":"130","author":"Schubart","year":"2011","journal-title":"Schizophr Res"},{"key":"2022031123345914900_B14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br J Pharmacol"},{"key":"2022031123345914900_B15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejphar.2009.03.010","article-title":"Time-dependent vascular actions of cannabidiol in the rat aorta","volume":"612","author":"O\u2019Sullivan","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"2022031123345914900_B16","doi-asserted-by":"crossref","first-page":"e28668","DOI":"10.1371\/journal.pone.0028668","article-title":"Cannabidiol reduces A\u03b2-induced neuroinflammation and promotes hippocampal neurogenesis through PPAR\u03b3 involvement","volume":"6","author":"Esposito","year":"2011","journal-title":"PLoS One"},{"key":"2022031123345914900_B17","doi-asserted-by":"crossref","first-page":"e28159","DOI":"10.1371\/journal.pone.0028159","article-title":"Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis","volume":"6","author":"De Filippis","year":"2011","journal-title":"PLoS One"},{"key":"2022031123345914900_B18","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/sj.bjp.0706414","article-title":"Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist","volume":"146","author":"Thomas","year":"2005","journal-title":"Br J Pharmacol"},{"key":"2022031123345914900_B19","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/sj.bjp.0707124","article-title":"The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo","volume":"150","author":"Pertwee","year":"2007","journal-title":"Br J Pharmacol"},{"key":"2022031123345914900_B20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1476-5381.2010.00756.x","article-title":"The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice","volume":"160","author":"Bolognini","year":"2010","journal-title":"Br J Pharmacol"},{"key":"2022031123345914900_B21","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/j.1528-1167.2010.02523.x","article-title":"\u0394\u2079-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats","volume":"51","author":"Hill","year":"2010","journal-title":"Epilepsia"},{"key":"2022031123345914900_B22","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1111\/j.1476-5381.2011.01410.x","article-title":"\u03948-Tetrahydrocannabivarin prevents hepatic ischaemia\/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors","volume":"165","author":"B\u00e1tkai","year":"2012","journal-title":"Br J Pharmacol"},{"key":"2022031123345914900_B23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1074\/jbc.M111.296020","article-title":"Modulation of L-\u03b1-lysophosphatidylinositol\/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids","volume":"287","author":"Anavi-Goffer","year":"2012","journal-title":"J Biol Chem"},{"key":"2022031123345914900_B24","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","article-title":"Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes","volume":"163","author":"De Petrocellis","year":"2011","journal-title":"Br J Pharmacol"},{"key":"2022031123345914900_B25","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1748-1716.2011.02338.x","article-title":"Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation","volume":"204","author":"De Petrocellis","year":"2012","journal-title":"Acta Physiol (Oxf)"},{"key":"2022031123345914900_B26","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/j.1476-5381.2008.00107.x","article-title":"Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice","volume":"156","author":"Riedel","year":"2009","journal-title":"Br J Pharmacol"},{"key":"2022031123345914900_B27","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1038\/nutd.2013.9","article-title":"The cannabinoid \u0394(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity","volume":"3","author":"Wargent","year":"2013","journal-title":"Nutr Diabetes"},{"key":"2022031123345914900_B28","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ab.2006.10.039","article-title":"Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry","volume":"360","author":"Richardson","year":"2007","journal-title":"Anal Biochem"},{"key":"2022031123345914900_B29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/sj.ijo.0801083","article-title":"Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies","volume":"24","author":"Flint","year":"2000","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2022031123345914900_B30","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/(SICI)1097-4679(199910)55:10<1307::AID-JCLP11>3.0.CO;2-7","article-title":"Beck depression inventory: exploring its dimensionality in a nonclinical population","volume":"55","author":"Endler","year":"1999","journal-title":"J Clin Psychol"},{"key":"2022031123345914900_B31","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.amjmed.2013.03.002","article-title":"The impact of marijuana use on glucose, insulin, and insulin resistance among US adults","volume":"126","author":"Penner","year":"2013","journal-title":"Am J Med"},{"key":"2022031123345914900_B32","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.mehy.2013.01.019","article-title":"Cannabis and \u03949-tetrahydrocannabinol (THC) for weight loss?","volume":"80","author":"Le Foll","year":"2013","journal-title":"Med Hypotheses"},{"key":"2022031123345914900_B33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/08916930500356674","article-title":"Cannabidiol lowers incidence of diabetes in non-obese diabetic mice","volume":"39","author":"Weiss","year":"2006","journal-title":"Autoimmunity"},{"key":"2022031123345914900_B34","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.neuropharm.2007.06.029","article-title":"Cannabidiol arrests onset of autoimmune diabetes in NOD mice","volume":"54","author":"Weiss","year":"2008","journal-title":"Neuropharmacology"},{"key":"2022031123345914900_B35","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s00210-004-0871-3","article-title":"Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw","volume":"369","author":"Costa","year":"2004","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2022031123345914900_B36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.nbd.2004.11.009","article-title":"Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson\u2019s disease","volume":"19","author":"Lastres-Becker","year":"2005","journal-title":"Neurobiol Dis"},{"key":"2022031123345914900_B37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1567-5688(02)00041-7","article-title":"Hugh sinclair lecture: the regulation and remodelling of HDL by plasma factors","volume":"3","author":"Barter","year":"2002","journal-title":"Atheroscler Suppl"},{"key":"2022031123345914900_B38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1055\/s-0031-1295491","article-title":"The metabolic role of retinol binding protein 4: an update","volume":"44","author":"Christou","year":"2012","journal-title":"Horm Metab Res"},{"key":"2022031123345914900_B39","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1463-1326.2005.00510.x","article-title":"Adiponectin--a key adipokine in the metabolic syndrome","volume":"8","author":"Whitehead","year":"2006","journal-title":"Diabetes Obes Metab"},{"key":"2022031123345914900_B40","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bph.12944","article-title":"Are cannabidiol and \u0394(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review","volume":"172","author":"McPartland","year":"2015","journal-title":"Br J Pharmacol"},{"key":"2022031123345914900_B41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35053000","article-title":"The hormone resistin links obesity to diabetes","volume":"409","author":"Steppan","year":"2001","journal-title":"Nature"},{"key":"2022031123345914900_B42","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1007\/s00125-009-1422-8","article-title":"Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications","volume":"52","author":"Irwin","year":"2009","journal-title":"Diabetologia"},{"key":"2022031123345914900_B43","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/10\/1777\/624535\/dc160650.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/10\/1777\/624535\/dc160650.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T18:37:28Z","timestamp":1647023848000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/39\/10\/1777\/129\/Efficacy-and-Safety-of-Cannabidiol-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,13]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,9,13]]},"published-print":{"date-parts":[[2016,10,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc16-0650","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,13]]}}}